Outlook Therapeutics Inc

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Outlook Therapeutics progresses well with ONS-5010, eyes global expansion

Outlook Therapeutics is well-positioned for potential approvals in Europe and the US in 2024 and 2025.
Strong financial backing and progress in key studies indicate a positive trajectory.
Challenges include addressing FDA queries and ensuring smart approval processes.
Opportunities lie in leveraging existing infrastructure, pricing discussions, and FDA agreements.

Outlook Therapeutics advances clinical trials and secures EU market entry

Outlook Therapeutics made significant progress with marketing authorization and clinical trial advancements.
Financial stability improved with reduced convertible notes and ample cash reserves.
Challenges lie in managing expenses, addressing analyst inquiries, and preparing for commercial launch.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced that it has entered into a Securities Purchase Agreement (“SPA”) with an accredited investor (the “lender”), and pursuant to the SPA, issued the lender an unsecured convertible promissory note (the “Note”) with a face amount of $31,820,000. The closing of the financing is expected to occur on December 28, 2022, subject to satisfaction of closing conditions, including the receipt of at least $25.0 million of equity financing. The proceeds from the Note and a previously announced equity financing, which remains subject to satisfaction of customary closing conditions, are expected to provide funding through the anticipated U.S. Food and Drug Administration approval of ONS-5010 expected in the third calendar quarter of 2023.

Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note

Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into securities purchase agreements with existing institutional and accredited investors for a registered direct offering priced at-the-market under Nasdaq rules. The offering is for the purchase and sale of 28,460,831 shares of common stock at a purchase price of $0.8784 per share, resulting in aggregate gross proceeds of approximately $25.0 million.

Outlook Therapeutics inks agreement with existing institutional and accredited investors for a registered direct offering priced at-the-market to raise $25M

ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into securities purchase agreements with existing institutional and accredited investors for the purchase and sale of 28,460,831 shares of common stock at a purchase price of $0.8784 per share in a registered direct offering priced at-the-market under Nasdaq rules, resulting in aggregate gross proceeds of approximately $25.0 million. The offering included participation by GMS Ventures and Investments, Outlook Therapeutics' largest stockholder. The offering is expected to close on December 28, 2022, subject to customary closing conditions.

Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook Therapeutics Inc (NASDAQ:OTLK) announced the validation of the company's Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for an investigational ophthalmic formulation of bevacizumab (ONS-5010) for the treatment of wet age-related macular degeneration (wet AMD). The formal review process of the application by the EMA's committee for medicinal products for human use (CHMP) is now set to begin and an estimated decision date is expected in early 2024.

Outlook Therapeutics announces validation of marketing authorization application by EMA for ONS-5010 as treatment for wet AMD

ISELIN, N.J., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the validation of its Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The formal review process of the MAA by the EMA's Committee for Medicinal Products for Human Use (CHMP) is now set to begin with an estimated decision date expected in early 2024.

Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to participate in a live moderated panel discussion on Thursday, December 8th at 2:45 PM ET

Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

ISELIN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present in a fireside chat at the virtual BTIG Ophthalmology Day on November 29, 2022 at 12:30 PM ET.

Outlook Therapeutics® to Present at the BTIG Ophthalmology Day

There's a question the CEO of Outlook Therapeutics Inc (NASDAQ:OTLK) likes to pose about why having US Food and Drug Administration (FDA)-approval will propel the company's upcoming treatment for retinal eye diseases to the top of the market. “Say I'm an eye care doctor.

Outlook Therapeutics says FDA approval for Lytenava will make huge difference for those with vision loss

Outlook Therapeutics Inc (NASDAQ:OTLK) said the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its investigational ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD).   The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of 29 August 2023.

Outlook Therapeutics encouraged by FDA acceptance of application for drug to treat retinal eye disease wet AMD

ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a Biologics License Application (BLA) for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023. ONS-5010, if approved, is expected to receive 12 years of regulatory exclusivity in the United States.

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

AmerisourceBergen

Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into a strategic relationship with healthcare company AmerisourceBergen in preparation for the anticipated commercial launch in the United States of its ONS-5010 treatment for wet age-related macular degeneration (AMD).  ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.

Outlook Therapeutics enters into commercialization agreement with AmerisourceBergen

ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, and AmerisourceBergen (NYSE: ABC), a global healthcare company and leader in specialty pharmaceutical distribution and services, announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).

Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will present at Eyecelerator @ AAO 2022 taking place Thursday, September 29, 2022 in Chicago, Illinois.

Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022

ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Outlook Therapeutics Inc (NASDAQ:OTLK) said it has re-submitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as LYTENAVA (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). Outlook Therapeutics CEO Russell Trenary said the company has worked diligently over the past three months to provide additional required information not included in its March 2022 submission.

Outlook Therapeutics re-submits biologics license application for ONS-5010 as a treatment for wet AMD to the FDA

ISELIN, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics (NASDAQ:OTLK) Inc, a pre-commercial biopharmaceutical company working to develop the first US Food and Drug Administration (FDA)-approved ophthalmic formulation of bevacizumab for use in retinal indications, said it has appointed Julia A Haller, MD, to the company's board of directors. "As one of the world's most accomplished professionals in ophthalmic education, research, and clinical ophthalmic practice, she will add tremendous value and insight to Outlook Therapeutics (NASDAQ:OTLK)," Randy Thurman, executive chair of Outlook Therapeutics said in a statement.

Outlook Therapeutics strengthens board with appointment of ophthalmologist Dr Julia Haller

ISELIN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointment of Julia A. Haller, MD, to the Company's Board of Directors.

Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD

Outlook Therapeutics (NASDAQ:OTLK) Inc said it ended the fiscal third quarter with $26 million in cash and cash equivalents that are expected to fund its work into the first calendar quarter of 2023, including advancing the company's ophthalmic formulation of bevacizumab towards US Food and Drug Administration (FDA) approval. In reporting its financial results for the three months ended June 30, 2022, the company highlighted a number of recent corporate milestones, including confirming its plans to re-submit a Biologics License Application (BLA) for ONS-5010 for the treatment of wet age-related macular degeneration (wet AMD) to the US FDA by September 2022.

Outlook Therapeutics ends 3Q with $26 million in cash and cash equivalents; plans to re-submit ONS-5010 application by September

Outlook Therapeutics (NASDAQ:OTLK) Inc has ended the fiscal third quarter with $26 million in cash and cash equivalents that are expected to fund its work into the first calendar quarter of 2023, including advancing the company's ophthalmic formulation of bevacizumab towards US Food and Drug Administration (FDA) approval. In reporting its financial results for the three months ended June 30, 2022, the company highlighted a number of recent corporate milestones, including confirming its plans to re-submit a Biologics License Application (BLA) for ONS-5010 for the treatment of wet age-related macular degeneration (wet AMD) to the US FDA by September 2022.

Outlook Therapeutics ends 3Q with $26 million in cash and cash equivalents; plans to re-submit ONS-5010 license application by September

ISELIN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced its financial results for its fiscal third quarter ended June 30, 2022, provided recent corporate highlights, and reiterated its anticipated near-term milestones.

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones

ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 2nd Annual Ophthalmology Conference being held virtually on Wednesday, August 17.

Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today the full cash pre-payment of its unsecured convertible promissory note dated November 4, 2020, as amended November 16, 2021 (the “Note”). All obligations under the Note have been repaid in cash and satisfied.

Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note

Outlook Therapeutics (NASDAQ:OTLK) Inc has provided an update on its Biologics License Application (BLA) submission for ONS-5010/LYTENAVA (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). The pre-commercial biopharmaceutical company said it has confirmed the additional information necessary to re-submit the BLA for ONS-5010 by September 2022 following receipt of additional correspondence from the US Food and Drug Administration (FDA).

Outlook Therapeutics confirms BLA re-submission date for its ONS-5010 wet AMD treatment

Bionano Genomics

Qudian

View

Penny stocks to watch right now. The post 4 Hot Penny Stocks To Watch After Big June 2022 News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Outlook Therapeutics Inc Stock (OTLK)